Virbac SA
PAR:VIRP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
280.6
364
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
VIRP
stock under the Base Case scenario is
286.61
EUR.
Compared to the current market price of 358.5 EUR,
Virbac SA
is
Overvalued by 20%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Virbac SA.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Virbac SA
Balance Sheet Decomposition
Virbac SA
| Current Assets | 842.2m |
| Cash & Short-Term Investments | 128.7m |
| Receivables | 289.8m |
| Other Current Assets | 423.7m |
| Non-Current Assets | 973.2m |
| Long-Term Investments | 4.4m |
| PP&E | 434.4m |
| Intangibles | 490.1m |
| Other Non-Current Assets | 44.4m |
| Current Liabilities | 430.5m |
| Accounts Payable | 154m |
| Accrued Liabilities | 60.2m |
| Short-Term Debt | 5.3m |
| Other Current Liabilities | 211m |
| Non-Current Liabilities | 319.8m |
| Long-Term Debt | 228.1m |
| Other Non-Current Liabilities | 91.7m |
Free Cash Flow Analysis
Virbac SA
| EUR | |
| Free Cash Flow | EUR |
Earnings Waterfall
Virbac SA
|
Revenue
|
1.8B
EUR
|
|
Cost of Revenue
|
-818.6m
EUR
|
|
Gross Profit
|
953.3m
EUR
|
|
Operating Expenses
|
-401.9m
EUR
|
|
Operating Income
|
551.5m
EUR
|
|
Other Expenses
|
-79.2m
EUR
|
|
Net Income
|
472.2m
EUR
|
VIRP Profitability Score
Profitability Due Diligence
Virbac SA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Virbac SA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
VIRP Solvency Score
Solvency Due Diligence
Virbac SA's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Virbac SA's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VIRP Price Targets Summary
Virbac SA
According to Wall Street analysts, the average 1-year price target for
VIRP
is 403.28 EUR
with a low forecast of 371.68 EUR and a high forecast of 441 EUR.
Dividends
Current shareholder yield for
VIRP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VIRP
stock under the Base Case scenario is
286.61
EUR.
Compared to the current market price of 358.5 EUR,
Virbac SA
is
Overvalued by 20%.